Parneet Cheema

7.2k total citations · 2 hit papers
98 papers, 2.1k citations indexed

About

Parneet Cheema is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Parneet Cheema has authored 98 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 74 papers in Pulmonary and Respiratory Medicine, 65 papers in Oncology and 23 papers in Cancer Research. Recurrent topics in Parneet Cheema's work include Lung Cancer Treatments and Mutations (72 papers), Lung Cancer Research Studies (29 papers) and Lung Cancer Diagnosis and Treatment (25 papers). Parneet Cheema is often cited by papers focused on Lung Cancer Treatments and Mutations (72 papers), Lung Cancer Research Studies (29 papers) and Lung Cancer Diagnosis and Treatment (25 papers). Parneet Cheema collaborates with scholars based in Canada, United States and France. Parneet Cheema's co-authors include Solange Peters, Barbara Melosky, Terufumi Kato, Charles M. Rudin, James Chih‐Hsin Yang, M. Catherine Pietanza, Gregory P. Kalemkerian, Maya Gottfried, Alejandro Navarro and Tibor Csőszi and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Parneet Cheema

93 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study

2020 491 citations Parneet Cheema et al. Journal of Clinical Oncology profile →
Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study

2019 319 citations Tony Mok, Parneet Cheema et al. profile →

Peers

Countries citing papers authored by Parneet Cheema

Since Specialization

Citations

This map shows the geographic impact of Parneet Cheema's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Parneet Cheema with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Parneet Cheema more than expected).

Fields of papers citing papers by Parneet Cheema

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Parneet Cheema. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Parneet Cheema. The network helps show where Parneet Cheema may publish in the future.

Co-authorship network of co-authors of Parneet Cheema

This figure shows the co-authorship network connecting the top 25 collaborators of Parneet Cheema. A scholar is included among the top collaborators of Parneet Cheema based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Parneet Cheema. Parneet Cheema is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Canadian Perspectives Revisited: Consensus on the management of ALK-rearranged NSCLC 2025 ·Lung Cancer ·Barbara Melosky, Quincy S. Chu, Rosalyn A. Juergens, Stephanie Snow, Normand Blais, Parneet Cheema, Randeep Sangha, Jason Agulnik, (unknown), Ronald L. Burkes, (unknown), Mark Vincent, Geoffrey Liu	0
2	The continually evolving landscape of novel therapies in oncogene-driven advanced non-small-cell lung cancer 2025 ·Therapeutic Advances in Medical Oncology ·Barbara Melosky, Rosalyn A. Juergens, Shantanu Banerji, Adrian G. Sacher, Paul Wheatley‐Price, Stephanie Snow, Ming‐Sound Tsao, Natasha B. Leighl, (unknown), Parneet Cheema, Geoffrey Liu, Quincy S. Chu	0
3	Programmed Cell Death-Ligand 1 Expression and Clinical Outcomes Among Patients with Resected, Early-Stage Non-Small Cell Lung Cancer: A Real-World Study 2024 ·Current Oncology ·Parneet Cheema, Iqra Syed, Femida Gwadry‐Sridhar, Muhammad Rakibuz‐Zaman, (unknown), (unknown), (unknown), Katrina Hueniken, Devalben Patel, (unknown), (unknown), (unknown), Brandon S. Sheffield, M. Locke, (unknown), (unknown), Geoffrey Liu, (unknown)	0
4	Implementation of Liquid Biopsy in Non-Small-Cell Lung Cancer: An Ontario Perspective 2024 ·Current Oncology ·Daniel Breadner, David Hwang, Don Husereau, Parneet Cheema, Sarah Doucette, Peter Ellis, (unknown), Natasha B. Leighl, Donna E. Maziak, Shamini Selvarajah, Brandon S. Sheffield, Rosalyn A. Juergens	2
5	Modern era systemic therapies: Expanding concepts of cure in early and locally advanced non‐small cell lung cancer 2024 ·International Journal of Cancer ·Barbara Melosky, Mark Vincent, Anna McGuire, Anthony Brade, Quincy S. Chu, Parneet Cheema, (unknown), Jonathan Spicer, Stephanie Snow, Rosalyn A. Juergens	3
6	Point of Care Liquid Biopsy for Cancer Treatment—Early Experience from a Community Center 2024 ·Cancers ·(unknown), (unknown), (unknown), (unknown), (unknown), Shaan Dudani, Marco Iafolla, Kashif Irshad, (unknown), (unknown), (unknown), David Chun Cheong Tsui, Xin Wang, (unknown), Parneet Cheema, Brandon S. Sheffield	6
7	Managing Select Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitors 2024 ·Current Oncology ·Parneet Cheema, Marco Iafolla, Husam Abdel‐Qadir, Alice Bellini, (unknown), Natasha Chandok, Vikram Comondore, Morven Cunningham, Ilana Halperin, (unknown), (unknown), Saeed Darvish‐Kazem, Masud H. Khandaker, Abhijat Kitchlu, (unknown), Shane Shapera, (unknown), (unknown)	7
8	KontRASt-02: A phase III trial investigating the efficacy and safety of the KRAS ^G12C inhibitor JDQ443 vs docetaxel in patients with previously treated, locally advanced or metastatic, KRAS G12C -mutated NSCLC. 2023 ·Journal of Clinical Oncology ·Federico Cappuzzo, Gilberto de Castro, Jin‐Hyoung Kang, Yi‐Long Wu, Odd Terje Brustugun, Parneet Cheema, Taofeek K. Owonikoko, (unknown), Aislyn Boran, (unknown), (unknown), Herbert H. Loong	8
9	Feasibility of Point-of-Care Genomic Profiling in the Diagnosis and Treatment of Cancer of Unknown Primary 2023 ·The Oncologist ·Xin Wang, (unknown), Brandon S. Sheffield, Parneet Cheema	4
10	Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC 2023 ·Current Oncology ·Parneet Cheema, Shantanu Banerji, Normand Blais, Quincy S. Chu, Rosalyn A. Juergens, Natasha B. Leighl, Adrian G. Sacher, Brandon S. Sheffield, Stephanie Snow, Mark Vincent, (unknown), Stephen Yip, Barbara Melosky	1
11	585P Real-world outcomes in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations receiving mobocertinib 2023 ·Annals of Oncology ·Tony Mok, Geoffrey Liu, (unknown), (unknown), Alexis B. Cortot, (unknown), R. Descourt, (unknown), Parneet Cheema, (unknown), Eric N. Churchill, (unknown), (unknown), (unknown), Kelly K. Chong, (unknown), (unknown), Jacques Cadranel	1
12	Canadian Consensus Recommendations on the Management of Extensive-Stage Small-Cell Lung Cancer 2023 ·Current Oncology ·Barbara Melosky, Natasha B. Leighl, David E. Dawe, Normand Blais, (unknown), Quincy S. Chu, Rosalyn A. Juergens, Peter Ellis, A. Sun, Devin Schellenberg, Diana N. Ionescu, Parneet Cheema	6
13	Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With MET Exon 14 Skipping Mutations: Efficacy and Toxicity as Sequential Therapies 2023 ·JTO Clinical and Research Reports ·(unknown), (unknown), Andrea S. Fung, (unknown), Jessica Weiss, (unknown), Geoffrey Liu, Penelope A. Bradbury, Frances A. Shepherd, Adrian G. Sacher, Harriet Feilotter, Brandon S. Sheffield, David Hwang, Ming‐Sound Tsao, Susanna Y. Cheng, Parneet Cheema, Natasha B. Leighl	4
14	Consensus Recommendations to Optimize Testing for New Targetable Alterations in Non-Small Cell Lung Cancer 2022 ·Current Oncology ·Diana N. Ionescu, Tracy Stockley, Shantanu Banerji, Christian Couture, (unknown), Zhaolin Xu, Normand Blais, Parneet Cheema, Quincy S. Chu, Barbara Melosky, Natasha B. Leighl	20
15	Point of Care Molecular Testing: Community-Based Rapid Next-Generation Sequencing to Support Cancer Care 2022 ·Current Oncology ·Brandon S. Sheffield, (unknown), (unknown), (unknown), Marco Iafolla, (unknown), Shaan Dudani, Mary Anne Brett, (unknown), Brian Olsen, Parneet Cheema	31
16	A Guide to Implementing Immune Checkpoint Inhibitors within a Cancer Program: Experience from a Large Canadian Community Centre 2022 ·Current Oncology ·Parneet Cheema, Marco Iafolla, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Shaan Dudani, (unknown), (unknown), Philip Kuruvilla, (unknown), Henry Jacob Conter	3
17	The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer 2021 ·Therapeutic Advances in Medical Oncology ·Barbara Melosky, Parneet Cheema, Rosalyn A. Juergens, Natasha B. Leighl, Geoffrey Liu, Paul Wheatley‐Price, Adrian G. Sacher, Stephanie Snow, Ming‐Sound Tsao, Deanna McLeod, Quincy S. Chu	4
18	The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer 2021 ·Lung Cancer ·Barbara Melosky, Paul Wheatley‐Price, Rosalyn A. Juergens, Adrian G. Sacher, Natasha B. Leighl, Ming‐Sound Tsao, Parneet Cheema, Stephanie Snow, Geoffrey Liu, (unknown), Quincy S. Chu	51
19	The Evolving Role of Immunotherapy in Stage III Non-Small Cell Lung Cancer 2021 ·Current Oncology ·(unknown), Parneet Cheema	2
20	Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model 2019 ·Lung Cancer ·(unknown), (unknown), William K. Evans, Parneet Cheema, Randeep Sangha, Ronald L. Burkes, Barbara Melosky, (unknown), (unknown), (unknown), (unknown), (unknown), Daniel Grima	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact